Annual report pursuant to Section 13 and 15(d)

Segment Information

v3.23.1
Segment Information
12 Months Ended
Dec. 31, 2022
Segment Information  
Segment Information

19. Segment Information

The Company operates in two reportable segments, Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results from continued operations by reportable segment:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Pharmaceutical

​

    

​

​

​

​

​

​

and

​

​

​

​

​

Dermatology

​

Biotechnology

​

​

​

​

​

Products

​

Product

​

​

​

Year Ended December 31, 2022

    

Sales

    

Development

    

Consolidated

Net revenue

​

$

73,669

​

$

2,074

​

$

75,743

Cost of goods - product revenue

​

 

(30,775)

​

 

—

​

 

(30,775)

Research and development

​

 

(10,943)

​

 

(123,933)

​

 

(134,876)

Selling, general and administrative

​

​

(59,503)

​

​

(54,153)

​

​

(113,656)

Other income

​

 

(2,048)

​

 

(7,852)

​

 

(9,900)

Income tax expense

​

​

—

​

​

(449)

​

​

(449)

Segment loss

​

$

(29,600)

​

$

(184,313)

​

$

(213,913)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Pharmaceutical

​

​

​

​

​

​

​

​

and

​

​

​

​

​

Dermatology

​

Biotechnology

​

​

​

​

​

Products

​

Product

​

​

​

Year Ended December 31, 2021

    

Sales

    

Development

    

Consolidated

Net revenue

​

$

63,134

​

$

5,657

​

$

68,791

Cost of goods - product revenue

​

 

(32,084)

​

 

—

​

​

(32,084)

Research and development

​

 

(16,558)

​

 

(112,307)

​

​

(128,865)

Selling, general and administrative

​

 

(39,895)

​

​

(46,948)

​

​

(86,843)

Wire transfer fraud loss

​

​

(9,540)

​

​

—

​

​

(9,540)

Other expense

​

​

(7,479)

​

 

31,667

​

​

24,188

Income tax expense

​

​

—

​

​

(473)

​

​

(473)

Segment income (loss)

​

$

(42,422)

​

$

(122,404)

​

$

(164,826)

​

The following tables summarize, for the periods indicated, total assets by reportable segment:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Pharmaceutical

​

    

​

​

​

​

​

​

and

​

​

​

($ in thousands)

​

Dermatology

​

Biotechnology

​

​

​

​

​

Products

​

Product

​

​

​

December 31, 2022

    

Sales

    

Development

    

Total Assets

Intangible assets, net

​

$

27,197

​

$

—

​

$

27,197

Tangible assets

​

​

77,964

​

​

189,140

​

​

267,104

Total segment assets

​

$

105,161

​

$

189,140

​

$

294,301

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Pharmaceutical

​

    

​

​

​

​

​

​

and

​

​

​

($ in thousands)

​

Dermatology

​

Biotechnology

​

​

​

​

​

Products

​

Product

​

​

​

December 31, 2021

    

Sales

    

Development

    

Total Assets

Intangible assets, net

​

$

12,552

​

$

—

​

$

12,552

Tangible assets

​

​

84,732

​

​

299,219

​

​

383,951

Total segment assets

​

$

97,284

​

$

299,219

​

$

396,503

​